- US12358920utility2025Substituted Pyrrolo[2,3-d]pyrimidines as Selective CDK 4/6 Inhibitors0 cites
- US12319690utility2025Selective CDK 4/6 Inhibitor Cancer Therapeutics0 cites
- US12208111utility2025Azithromycin and Roxithromycin Derivtives as Senolytic Drugs0 cites
- US12188936utility2025Biomarkers and Therapeutics for Endocrine Therapy Resistance0 cites
- US12006553utility2024Companion Diagnostics for Mitochondrial Inhibitors0 cites
- US11964983utility2024Selective CDK4/6 Inhibitor Cancer Therapeutics0 cites
- US11957700utility2024Azithromycin and Roxithromycin Derivatives as Senolytic Drugs0 cites
- US11918597utility2024Triple Combination Therapies for Anti-aging0 cites
- US11865124utility2024Vitamin C and Doxycycline: a Synthetic Lethal Combination Therapy for Eradicating Cancer Stem Cells (CSCS)0 cites
- US11865130utility2024Antimitoscins: Targeted Inhibitors of Mitochondrial Biogenesis for Eradicating Cancer Stem Cells0 cites
- US11738034utility2023Triphenylphosphonium-derivative Compounds for Eradicating Cancer Stem Cells0 cites
- US11672810utility2023Therapeutics and Methods for Predicting and Overcoming Endocrine Resistance in Breast Cancer0 cites
- US11667639utility2023Mitoketoscins: Mitochondrial-based Therapeutics Targeting Ketone Metabolism in Cancer Cells0 cites
- US11667640utility2023Mitoketoscins: Mitochondrial-based Therapeutics Targeting Ketone Metabolism in Cancer Cells0 cites
- US11559527utility2023Targeting Mitochondrial Fission Through Mdivi-1 Derivatives0 cites
- US11561227utility2023Anti-mitochondrial Inhibitors for Oncogenic Ras and Myc0 cites
- US11547679utility2023Mitoriboscins: Mitochondrial-based Therapeutics Targeting Cancer Cells, Bacteria and Pathogenic Yeast0 cites